Intranasal bacille Calmette-Guérin (BCG) vaccine dosage needs balancing between protection and lung pathology

Clinical and Experimental Immunology

Volumn 138, Issue 3, 2004, Pages 405-409

  Tree, J A ^a   Williams, A ^a   Clark, S ^a   Hall, G ^a   Marsh, P D ^a   Ivanyi, Juraj ^b,c  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c GUY S HOSPITAL   (United Kingdom)

Author keywords

BCG; Intranasal vaccination; Lung granuloma; Tuberculosis; Vaccine dosage

Indexed keywords

BCG VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BCG VACCINATION; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; LUNG; LUNG GRANULOMA; LUNG TUBERCULOSIS; MYCOBACTERIUM BOVIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SPLEEN; TREATMENT OUTCOME;

ADMINISTRATION, INTRANASAL; ANIMALS; BCG VACCINE; COLONY COUNT, MICROBIAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; GRANULOMA; INJECTIONS, SUBCUTANEOUS; LUNG; LUNG DISEASES; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; MYCOBACTERIUM BOVIS; SPLEEN; TUBERCULOSIS;

EID: 9644265109     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2004.02648.x     Document Type: Article

References (24)

1. Falero-Diaz G, Challacombe S, Banerjee D, Douce G, Boyd A, Ivanyi J. Intranasal vaccination of mice against infection with Mycobacterium tuberculosis. Vaccine 2000; 18:3223-9.
2. Lyadova IV, Vordermeier HM, Eruslanov EB, Khaidukov SV, Apt AS, Hewinson RG. Intranasal BCG vaccination protects BALB/c mice against virulent Mycobacterium bovis and accelerates production of IFN-gamma in their lungs. Clin Exp Immunol 2001; 126:274-9.
3. Chen L, Wang J, Zganiacz A, Xing Z. Single intranasal mucosal Mycobacterium bovis BCG vaccination confers improved protection compared to subcutaneous vaccination against pulmonary tuberculosis. Infect Immun 2004; 72:238-46.
4. Nuermberger EL, Yoshimatsu T, Tyagi S, Bishai WR, Grosset JH. Paucibacillary tuberculosis in mice after prior aerosol immunization with Mycobacterium bovis BCG. Infect Immun 2004; 72:1065-71.
5. Hodge LM, Marinaro M, Jones HP, McGhee JR, Kiyono H, Simecka JW. Immunoglobulin A (IgA) responses and IgE-associated inflammation along the respiratory tract after mucosal but not systemic immunization. Infect Immun 2001; 69:2328-38.
6. Power CA, Wei G, Bretscher PA. Mycobacterial dose defines the Th1/Th2 nature of the immune response independently of whether immunization is administered by the intravenous, subcutaneous, or intradermal route. Infect Immun 1998; 66:5743-50.
7. Gruppo V, Orme IM. Dose of BCG does not influence the efficient generation of protective immunity in mice challenged with Mycobacterium tuberculosis. Tuberculosis (Edinb) 2002; 82:267-73.
8. Abolhassani M, Lagranderie M, Chavarot P, Balazuc AM, Marchal G. Mycobacterium bovis BCG induces similar immune responses and protection by rectal and parenteral immunization routes. Infect Immun 2000; 68:5657-62.
9. Lagranderie M, Chavarot P, Balazuc AM, Marchal G. Immunogenicity and protective capacity of Mycobacterium bovis BCG after oral or intragastric administration in mice. Vaccine 2000; 18:1186-95.
10. James BW, Williams A, Marsh PD. The physiology and pathogenicity of Mycobacterium tuberculosis grown under controlled conditions in a denned medium. J Appl Microbiol 2000; 88:669-77.
11. Druett HA. A mobile form of the Henderson apparatus. J Hygiene (Lond) 1969; 67:437-48.
12. Skamene E. The Beg gene story. Immunobiology 1994; 191:451-60.
13. Wakeham J, Wang J, Xing Z. Genetically determined disparate innate and adaptive cell-mediated immune responses to pulmonary Mycobacterium bovis BCG infection in C57BL/6 and BALB/c mice. Infect Immun 2000; 68:6946-53.
14. Medina E, Rogerson BJ, North RJ. The Nramp1 antimicrobial resistance gene segregates independently of resistance to virulent Mycobacterium tuberculosis. Immunology 1996; 88:479-81.
15. Lowry PW, Ludwig TS, Adams JA et al. Cellular immune responses to four doses of percutaneous bacille Calmette-Guérin in healthy adults. J Infect Dis 1998; 178:138-46.
16. Palendira U, Bean AG, Feng CG, Britton WJ. Lymphocyte recruitment and protective efficacy against pulmonary mycobacterial infection are independent of the route of prior Mycobacterium bovis BCG immunization. Infect Immun 2002; 70:1410-6.
17. Murray PJ, Aldovini A, Young RA. Manipulation and potentiation of antimycobacterial immunity using recombinant bacille Calmette-Guérin strains that secrete cytokines. Proc Natl Acad Sci USA 1996; 93:934-9.
18. Marshall BG, Wangoo A, O'Gaora P, Cook HT, Shaw RJ, Young DB. Enhanced antimycobacterial response to recombinant Mycobacterium bovis BCG expressing latency-associated peptide. Infect Immun 2001; 69:6676-82.
19. Smith D, Hansch H, Bancroft G, Ehlers S. T-cell-independent granuloma formation in response to Mycobacterium avium: role of tumour necrosis factor-alpha and interferon-gamma. Immunology 1997; 92:413-21.
20. Actor JK, Olsen M, Hunter RL Jr, Geng YJ. Dysregulated response to mycobacterial cord factor trehalose-6,6′-dimycolate in CD1D-/- mice. J Interferon Cytokine Res 2001; 21:1089-96.
21. Smith DA, Parish T, Stoker NG, Bancroft GJ. Characterization of auxotrophic mutants of Mycobacterium tuberculosis and their potential as vaccine candidates. Infect Immun 2001; 69:1142-50.
22. D'Souza S, Rosseels V, Denis O et al. Improved tuberculosis DNA vaccines by formulation in cationic lipids. Infect Immun 2002; 70:3681-8.
23. Rodriguez A, Troye-Blomberg M, Lindroth K, Ivanyi J, Singh M, Fernandez C. B- and T-cell responses to the mycobacterium surface antigen PstS-1 in the respiratory tract and adjacent tissues. Role of adjuvants and routes of immunization. Vaccine 2003; 21:458-67.
24. Kumar M, Behera AK, Matsuse H, Lockey RF, Mohapatra SS. A recombinant BCG vaccine generates a Th1-like response and inhibits IgE synthesis in BALB/c mice. Immunology 1999; 97:515-21.